Assignee
ALDEYRA THERAPEUTICS INC
US·37 granted patents·27 pending applications·462 citations·filing 2014–2024
Top patents by PatentIndex Score
64 records- 0198US11724987B2Compositions and methods of treating retinal diseaseALDEYRA THERAPEUTICS INC·Filed 2021·Granted Aug 15, 2023·7 cites·9 claims
- 0298US11007157B2Toxic aldehyde related diseases and treatmentALDEYRA THERAPEUTICS INC·Filed 2020·Granted May 18, 2021·15 cites·41 claims
- 0398US10913722B2Compositions and methods of treating retinal diseaseALDEYRA THERAPEUTICS INC·Filed 2019·Granted Feb 9, 2021·15 cites·8 claims
- 0498US10202348B2Compositions and methods of treating retinal diseaseALDEYRA THERAPEUTICS INC·Filed 2018·Granted Feb 12, 2019·25 cites·9 claims
- 0598US9896419B2Compositions and methods of treating retinal diseaseALDEYRA THERAPEUTICS INC·Filed 2017·Granted Feb 20, 2018·28 cites·6 claims
- 0698US9650342B2Compositions and methods of treating retinal diseaseALDEYRA THERAPEUTICS INC·Filed 2016·Granted May 16, 2017·28 cites·11 claims
- 0797US11771664B2Toxic aldehyde related diseases and treatmentALDEYRA THERAPEUTICS INC·Filed 2022·Granted Oct 3, 2023·4 cites·16 claims
- 0897US11701331B2Toxic aldehyde related diseases and treatmentALDEYRA THERAPEUTICS INC·Filed 2021·Granted Jul 18, 2023·7 cites·41 claims
- 0997US11459300B2Deuterated compounds and uses thereofALDEYRA THERAPEUTICS INC·Filed 2021·Granted Oct 4, 2022·10 cites·20 claims
- 1097US11046650B2Deuterated compounds and uses thereofALDEYRA THERAPEUTICS INC·Filed 2019·Granted Jun 29, 2021·16 cites·19 claims
- 1197US10550085B2Deuterated compounds and uses thereofALDEYRA THERAPEUTICS INC·Filed 2016·Granted Feb 4, 2020·20 cites·20 claims
- 1296US11845722B2Deuterated compounds and uses thereofALDEYRA THERAPEUTICS INC·Filed 2022·Granted Dec 19, 2023·7 cites·22 claims
- 1396US11197821B2Formulations for treatment of dry eye diseaseALDEYRA THERAPEUTICS INC·Filed 2019·Granted Dec 14, 2021·12 cites·24 claims
- 1496US10588874B2Toxic aldehyde related diseases and treatmentALDEYRA THERAPEUTICS INC·Filed 2019·Granted Mar 17, 2020·20 cites·41 claims
- 1596US10543181B2Toxic aldehyde related diseases and treatmentALDEYRA THERAPEUTICS INC·Filed 2019·Granted Jan 28, 2020·17 cites·30 claims
- 1696US10213395B2Toxic aldehyde related diseases and treatmentALDEYRA THERAPEUTICS INC·Filed 2017·Granted Feb 26, 2019·24 cites·40 claims
- 1796US9364471B2Compositions and methods of treating retinal diseaseALDEYRA THERAPEUTICS INC·Filed 2014·Granted Jun 14, 2016·26 cites·13 claims
- 1896US9265759B2Compositions and methods of treating retinal diseaseALDEYRA THERAPEUTICS INC·Filed 2014·Granted Feb 23, 2016·28 cites·5 claims
- 1995US12097188B2Compositions and methods for the treatment of macular degenerationALDEYRA THERAPEUTICS INC·Filed 2023·Granted Sep 24, 2024·1 cites·19 claims
- 2095US11129823B2Combination treatment of ocular inflammatory disorders and diseasesALDEYRA THERAPEUTICS INC·Filed 2017·Granted Sep 28, 2021·12 cites·4 claims
- 2195US9687481B2Toxic aldehyde related diseases and treatmentALDEYRA THERAPEUTICS INC·Filed 2014·Granted Jun 27, 2017·28 cites·35 claims
- 2295US2025127733A1Toxic aldehyde related diseases and treatmentALDEYRA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2394US11312692B1Polymorphic compounds and uses thereofALDEYRA THERAPEUTICS INC·Filed 2021·Granted Apr 26, 2022·11 cites·19 claims
- 2494US10426790B2Treatment of allergic eye conditions with cyclodextrinsALDEYRA THERAPEUTICS INC·Filed 2017·Granted Oct 1, 2019·20 cites·30 claims
- 2594US10111862B2Traps in the treatment of macular degenerationALDEYRA THERAPEUTICS INC·Filed 2014·Granted Oct 30, 2018·26 cites·24 claims
- 2693US11786518B2Ophthalmic formulations and uses thereofALDEYRA THERAPEUTICS INC·Filed 2020·Granted Oct 17, 2023·7 cites·23 claims
- 2793US11583529B2Treatment of inflammatory disordersALDEYRA THERAPEUTICS INC·Filed 2021·Granted Feb 21, 2023·7 cites·6 claims
- 2893US11040039B2Treatment of inflammatory disordersALDEYRA THERAPEUTICS INC·Filed 2018·Granted Jun 22, 2021·16 cites·7 claims
- 2993US10414732B2Polymorphic compounds and uses thereofALDEYRA THERAPEUTICS INC·Filed 2018·Granted Sep 17, 2019·20 cites·15 claims
- 3092US12128013B2Toxic aldehyde related diseases and treatmentALDEYRA THERAPEUTICS INC·Filed 2023·Granted Oct 29, 2024·0 cites·20 claims
- 3192US11911385B1Methotrexate treatment methodsALDEYRA THERAPEUTICS INC·Filed 2022·Granted Feb 27, 2024·1 cites·20 claims
- 3288US2024174614A1Compositions and methods of treating retinal diseaseALDEYRA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3386US12064516B2Pharmaceutical formulations and uses thereofALDEYRA THERAPEUTICS INC·Filed 2021·Granted Aug 20, 2024·1 cites·10 claims
- 3485US2025144080A1Compositions and methods for the treatment of macular degenerationALDEYRA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3584US12240816B2Deuterated compounds and uses thereofALDEYRA THERAPEUTICS INC·Filed 2023·Granted Mar 4, 2025·0 cites·20 claims
- 3684US2023041335A1Compositions and methods of treating retinal diseaseALDEYRA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3781US12029735B2Polymorphic compounds and uses thereofALDEYRA THERAPEUTICS INC·Filed 2021·Granted Jul 9, 2024·1 cites·21 claims
- 3880US12005061B2Ophthalmic formulations of methotrexateALDEYRA THERAPEUTICS INC·Filed 2022·Granted Jun 11, 2024·0 cites·27 claims
- 3979US12098132B2Process for preparation of aldehyde scavenger and intermediatesALDEYRA THERAPEUTICS INC·Filed 2020·Granted Sep 24, 2024·1 cites·9 claims
- 4079US12006298B2Polymorphic compounds and uses thereofALDEYRA THERAPEUTICS INC·Filed 2019·Granted Jun 11, 2024·1 cites·20 claims
- 4178US12005060B2Ophthalmic formulations of methotrexateALDEYRA THERAPEUTICS INC·Filed 2022·Granted Jun 11, 2024·0 cites·16 claims
- 4277US2023293527A1Treatment of inflammatory disordersALDEYRA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4375US2023248727A1Treatment of inflammatory disordersALDEYRA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4474US2024197740A1Methotrexate treatment methodsALDEYRA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4570US2024139173A1Ophthalmic formulations and uses thereofALDEYRA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4668US2022354857A1Aldehyde conjugates and uses thereofALDEYRA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4766US2022133629A1Formulations for treatment of dry eye diseaseALDEYRA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4866US2020246345A1Aldehyde conjugates and uses thereofALDEYRA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4965US2022370460A1Ophthalmic formulations of methotrexateALDEYRA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 5064US2022184057A1Combination treatment of ocular inflammatory disorders and diseasesALDEYRA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
Showing the top 50 of 64 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when ALDEYRA THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →